跳转至内容
Merck
CN

主要文件

查看所有文档

H-004

氢吗啡酮标准液 溶液

1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C17H19NO3
化学文摘社编号:
466-99-9
分子量:
285.34
NACRES:
NA.24
PubChem Substance ID:
329815100
UNSPSC Code:
41116107
EC Number:
200-659-6
MDL number:
MFCD00864214
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

grade

certified reference material

Quality Level

300

form

liquid

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal), kontrollierte Droge in Deutschland

concentration

1 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

CN1CC[C@@]23[C@H]4CCC(=O)[C@@H]2Oc5c(O)ccc(C[C@@H]14)c35

InChI

1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1

InChI key

WVLOADHCBXTIJK-YNHQPCIGSA-N

Gene Information

human ... OPRM1(4988)

General description

该认证参考标准品适合用作校准品或对照品的原材料，用于从法医分析、临床毒理学、止痛药处方监测到尿液药物测试和药物研究等各种 LC/MS 或 GC/MS 应用。 氢吗啡酮，商品名为Palladone和Dilaudid®，是一种强效的阿片类镇痛药。该药通常在医学上用作吗啡的替代品，用于治疗疼痛或作为止咳药治疗持续性支气管刺激引起的疼痛性咳嗽。

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Dilaudid is a registered trademark of Purdue Pharma L.P.

Disclaimer

Supply conditions do not apply to the regions and states of Brazil: North, Northeast, Mato Grosso do Sul, Mato Grosso, and Rio Grande do Sul.

Still not finding the right product?

Explore all of our products under 氢吗啡酮标准液 溶液

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

存储类别

3 - Flammable liquids

wgk

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

法规信息

监管及禁止进口产品

此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

实验方案

使用UHPLC/MS（TOF）检测不同酶水解条件处理的尿液中药物和代谢物

为了使用β-葡糖醛酸酶优化水解，必须对每种待分析的葡糖苷酸代谢物进行某些因素的评估，例如孵育时间、温度、水解pH、酶源和酶浓度。

UHPLC/MS for Drug Detection in Urine

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

LC/MS (TOF) Analysis of Drugs and Their Glucuronide Metabolites in Urine on Titan™ C18 After Solid Phase Extraction (SPE) Using Supel™-Select SCX, β-Glucuronidase Enzyme Digestion

-THC solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

商品

Benefits of Ascentis Express Phenyl-Hexyl over Biphenyl for the Separation of Pain Management Opiates

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Kyung Hee Lee et al.
Journal of opioid management, 8(4), 243-252 (2012-09-04)
To evaluate the effectiveness of OROS® hydromorphone in reducing breakthrough pain (BTP) medication frequency in Korean patients with chronic cancer pain. Multicenter, prospective, open-label, phase IV study. Patients with chronic malignant pain using immediate-release oxycodone more than two times per
Bonnie L Hay Kraus
Veterinary anaesthesia and analgesia, 40(1), 28-34 (2012-10-23)
The goal of this study was to evaluate the effectiveness of maropitant (Cerenia(®)) in preventing vomiting after premedication with hydromorphone. Randomized, blinded, prospective clinical study. Eighteen dogs ASA I/II admitted for elective orthopedic surgical procedures. The dogs were a mixed
Martin E Hale et al.
Journal of opioid management, 8(5), 299-314 (2012-12-19)
This analysis was designed to assess the pooled safety and tolerability of once-daily hydromorphone extended release (ER) (OROS® hydromorphone ER) in opioid-naïve and opioid-tolerant patients with chronic cancer or noncancer pain. Safety results were pooled from 13 controlled and uncontrolled
查看所有相关文献

全球贸易项目编号

货号GTIN
H-004-1ML04061833660300